New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis.

IL-17A inhibitors ankylosing spondylitis biologics iritis secukinumab spondyloarthritis uveitis

Journal

International medical case reports journal
ISSN: 1179-142X
Titre abrégé: Int Med Case Rep J
Pays: New Zealand
ID NLM: 101566269

Informations de publication

Date de publication:
2020
Historique:
received: 15 06 2020
accepted: 24 07 2020
entrez: 18 8 2020
pubmed: 18 8 2020
medline: 18 8 2020
Statut: epublish

Résumé

Secukinumab, "an IL-17 antagonist", is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a case of a new-onset anterior uveitis after 6 months of starting secukinumab in a 47-year-old male, HLA-B27 positive AS patient. He had a long-standing history with the disease over 25 years. He was treated in the past with methotrexate then adalimumab and later on with etanercept. He had no history of uveitis during all of this time. The uveitis was mild and treated conventionally with local measures while secukinumab was maintained. After a close follow-up, the uveitis had completely resolved. Is this part of the original disease or a possible side effect from secukinumab?

Identifiants

pubmed: 32801946
doi: 10.2147/IMCRJ.S265812
pii: 265812
pmc: PMC7415454
doi:

Types de publication

Case Reports

Langues

eng

Pagination

331-334

Informations de copyright

© 2020 Nadwi et al.

Déclaration de conflit d'intérêts

Hani Almoallim reports this work was supervised and funded by Alzaidi Chair of Research in Rheumatic, Umm Alqura University, Makkah, Saudi Arabia. The authors report no other potential conflicts of interest for this work.

Références

Arthritis Rheumatol. 2016 Feb;68(2):282-98
pubmed: 26401991
Curr Med Res Opin. 2014 Dec;30(12):2515-21
pubmed: 25252590
Lancet. 2007 Apr 21;369(9570):1379-1390
pubmed: 17448825
Clin Rheumatol. 2015 Jun;34(6):999-1002
pubmed: 25953065
ACR Open Rheumatol. 2020 May;2(5):294-299
pubmed: 32352653
Eur J Intern Med. 2011 Dec;22(6):554-60
pubmed: 22075279
Ann Rheum Dis. 2015 Jan;74(1):65-73
pubmed: 23999006
Ophthalmology. 2013 Apr;120(4):777-87
pubmed: 23290985
Surv Ophthalmol. 2005 Jul-Aug;50(4):364-88
pubmed: 15967191
RMD Open. 2019 Sep 3;5(2):e001005
pubmed: 31565244
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299
pubmed: 31436026
Ophthalmology. 2015 May;122(5):939-48
pubmed: 25638011

Auteurs

Huda Nadwi (H)

Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia.

Murad Janaini (M)

Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia.

Mohammed Zammo (M)

Department of Medicine, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.

Mohamed Cheikh (M)

Department of Medicine, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.

Hani Almoallim (H)

Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia.
Department of Medicine, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Alzaidi Chair of Research in Rheumatic Diseases, Umm Alqura University, Makkah, Saudi Arabia.

Classifications MeSH